LU92666I2 - Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate - Google Patents

Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate Download PDF

Info

Publication number
LU92666I2
LU92666I2 LU92666C LU92666C LU92666I2 LU 92666 I2 LU92666 I2 LU 92666I2 LU 92666 C LU92666 C LU 92666C LU 92666 C LU92666 C LU 92666C LU 92666 I2 LU92666 I2 LU 92666I2
Authority
LU
Luxembourg
Prior art keywords
dasabuvir
sodium monohydrate
salt therefrom
salt
crystalline forms
Prior art date
Application number
LU92666C
Other languages
English (en)
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of LU92666I2 publication Critical patent/LU92666I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU92666C 2007-09-17 2015-02-25 Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate LU92666I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97288107P 2007-09-17 2007-09-17
US9679208P 2008-09-13 2008-09-13
PCT/US2008/076592 WO2009039134A1 (fr) 2007-09-17 2008-09-17 Agents anti-infectieux et leurs utilisations

Publications (1)

Publication Number Publication Date
LU92666I2 true LU92666I2 (fr) 2015-11-24

Family

ID=40308557

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92666C LU92666I2 (fr) 2007-09-17 2015-02-25 Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate

Country Status (22)

Country Link
US (3) US8188104B2 (fr)
EP (3) EP2203431B1 (fr)
JP (3) JP5734655B2 (fr)
CN (4) CN104628654A (fr)
AT (1) ATE519746T1 (fr)
CA (2) CA2699986C (fr)
CY (3) CY1115514T1 (fr)
DK (3) DK2368882T3 (fr)
ES (3) ES2523864T3 (fr)
HK (2) HK1148273A1 (fr)
HR (2) HRP20110809T1 (fr)
HU (1) HUS1500013I1 (fr)
LT (1) LTC2203431I2 (fr)
LU (1) LU92666I2 (fr)
MX (1) MX2010002902A (fr)
NL (1) NL300729I2 (fr)
NO (1) NO2015011I1 (fr)
PL (3) PL2203431T3 (fr)
PT (3) PT2203431E (fr)
RU (2) RU2014147354A (fr)
SI (2) SI2203431T1 (fr)
WO (1) WO2009039134A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746239B (zh) 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
US8178548B2 (en) 2007-09-17 2012-05-15 Abbott Laboratories Anti-infective agents and uses thereof
RU2014147354A (ru) * 2007-09-17 2015-07-10 Эббви Бахамаз Лтд. Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения
CA2730517A1 (fr) * 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Composes antiviraux heterocycliques
BRPI0920513A2 (pt) 2008-09-26 2019-09-24 F Hoffamann La Roche Ag derivados de pirina ou pirazina para tratar hcv
WO2010043721A1 (fr) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Inhibiteurs d’oxydases et leur utilisation
EP2389362B1 (fr) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Dérivés de phénylcyclopropylamine et leur utilisation médicale
CN102448952B (zh) * 2009-03-25 2014-10-29 Abbvie公司 抗病毒化合物和其用途
EP2421831A1 (fr) 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Composes antiviraux heterocycliques
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
TW201103545A (en) 2009-06-24 2011-02-01 Hoffmann La Roche Heterocyclic antiviral compound
MX2012003170A (es) 2009-09-21 2012-04-11 Hoffmann La Roche Compuestos heterociclicos antivirales.
CN102639496B (zh) 2009-09-25 2014-10-29 奥瑞泽恩基因组学股份有限公司 赖氨酸特异性脱甲基酶-1抑制剂及其应用
EP2486002B1 (fr) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Acétamides d'hétéroaryl- et aryl-cyclopropylamine substitués et leur utilisation
WO2011061243A1 (fr) * 2009-11-21 2011-05-26 F. Hoffmann-La Roche Ag Composés antiviraux hétérocycliques
US9062015B2 (en) * 2009-12-14 2015-06-23 Merck Patent Gmbh Inhibitors of sphingosine kinase
CN102652134A (zh) * 2009-12-14 2012-08-29 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106573A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase utilisés dans le traitement et la prévention de maladies et de troubles associés à hepadnaviridae
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
BR112012026694A2 (pt) 2010-04-19 2016-07-12 Oryzon Genomics Sa inibidores da desmetilase específica para lisina 1 e seu uso
CN103097027B (zh) 2010-07-16 2017-03-08 艾伯维巴哈马有限公司 用于催化反应的膦配体
SG187102A1 (en) 2010-07-16 2013-02-28 Abbvie Inc Process for preparing antiviral compounds
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
WO2012013728A1 (fr) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Inhibiteurs de déméthylase lsd1 base d'aryclcyclopropylamine et leur utilisation médicale
WO2012013727A1 (fr) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1
WO2012020725A1 (fr) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Dérivé hétérocyclique présentant un antagonisme pour le récepteur npy y5
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (fr) * 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase spécifique de la lysine pour des maladies et troubles liés aux flaviviridés
WO2012107498A1 (fr) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Inhibiteurs de lysine diméthylase pour des troubles myéloprolifératifs
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
SG11201401066PA (en) 2011-10-20 2014-10-30 Oryzon Genomics Sa (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
RU2681211C2 (ru) 2011-10-20 2019-03-05 Оризон Дженомикс С.А. (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) * 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
JP6469571B2 (ja) 2012-08-21 2019-02-13 アッヴィ・アイルランド・アンリミテッド・カンパニー 抗ウイルス性化合物を調製するための方法
AU2013330993B2 (en) * 2012-10-18 2018-03-01 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
EP3089757A1 (fr) 2014-01-03 2016-11-09 AbbVie Inc. Formes galéniques antivirales solides
CN106065009B (zh) * 2014-06-28 2019-03-01 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用
WO2016105547A1 (fr) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Dasabuvir deutéré
EA039557B1 (ru) * 2016-03-17 2022-02-10 Фмк Корпорейшн Способ превращения s-энантиомера в его рацемическую форму
WO2017189978A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
CN108290844B (zh) * 2016-05-27 2021-04-30 深圳市塔吉瑞生物医药有限公司 一种取代的萘环化合物及药物组合物及其应用
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US5084084A (en) * 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
CA2036304C (fr) * 1990-02-15 2001-04-17 Takehiko Naka Derives de la pyrimidinedione; preparation et utilisation
NL9001075A (fr) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (fr) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Dérivés d'uracile et herbicides les contenant comme ingrédient actif
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
BR0016195A (pt) 1999-12-06 2002-08-13 Hoffmann La Roche 4-pirimidinil-n-acil-l-fenilalaninas
IL141034A0 (en) * 2000-02-04 2002-02-10 Sumitomo Chemical Co Uracil compounds and use thereof
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
BR0307712A (pt) * 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
CN1717396A (zh) * 2002-11-28 2006-01-04 舍林股份公司 Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
US7511145B2 (en) * 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
MX2007000481A (es) * 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
AR057986A1 (es) * 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
CN102746239B (zh) * 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
RU2014147354A (ru) 2007-09-17 2015-07-10 Эббви Бахамаз Лтд. Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения
US8178548B2 (en) 2007-09-17 2012-05-15 Abbott Laboratories Anti-infective agents and uses thereof
CA2730517A1 (fr) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Composes antiviraux heterocycliques

Also Published As

Publication number Publication date
PT2368882E (pt) 2014-11-27
WO2009039134A1 (fr) 2009-03-26
NL300729I1 (fr) 2016-01-07
HK1148273A1 (en) 2011-09-02
DK2639226T3 (en) 2016-12-19
CY1115514T1 (el) 2016-04-13
EP2203431A1 (fr) 2010-07-07
CA2699986C (fr) 2014-06-17
RU2014147354A3 (fr) 2018-07-30
CN104628655A (zh) 2015-05-20
SI2368882T1 (sl) 2015-02-27
US8501238B2 (en) 2013-08-06
PL2639226T3 (pl) 2017-02-28
HRP20141102T1 (en) 2015-03-13
CN102746240B (zh) 2017-10-03
CY1115893T1 (el) 2017-01-25
US20090186912A1 (en) 2009-07-23
EP2639226B1 (fr) 2016-08-31
JP5734655B2 (ja) 2015-06-17
ES2523864T3 (es) 2014-12-02
DK2203431T3 (da) 2011-11-21
CN102746240A (zh) 2012-10-24
EP2368882B1 (fr) 2014-08-13
CN101842360B (zh) 2014-12-17
CY2015013I2 (el) 2016-04-13
RU2010114827A (ru) 2011-10-27
PT2639226T (pt) 2016-12-09
US20140294766A1 (en) 2014-10-02
PT2203431E (pt) 2011-10-12
EP2368882A1 (fr) 2011-09-28
ES2368879T3 (es) 2011-11-23
HRP20110809T1 (hr) 2011-12-31
NL300729I2 (fr) 2016-01-07
EP2203431B1 (fr) 2011-08-10
US8188104B2 (en) 2012-05-29
SI2203431T1 (sl) 2011-12-30
ATE519746T1 (de) 2011-08-15
US20120244119A1 (en) 2012-09-27
NO2015011I2 (no) 2015-04-22
CY2015013I1 (el) 2016-04-13
LTC2203431I2 (lt) 2017-01-25
RU2539570C2 (ru) 2015-01-20
CN104628654A (zh) 2015-05-20
EP2639226A1 (fr) 2013-09-18
CA2699986A1 (fr) 2009-03-26
NO2015011I1 (no) 2015-05-04
JP2015187106A (ja) 2015-10-29
HK1156033A1 (en) 2012-06-01
CA2849420A1 (fr) 2009-03-26
MX2010002902A (es) 2010-06-02
PL2368882T3 (pl) 2015-04-30
HUS1500013I1 (hu) 2016-11-28
CA2849420C (fr) 2016-07-12
CN101842360A (zh) 2010-09-22
DK2368882T3 (en) 2014-12-01
US9139536B2 (en) 2015-09-22
JP5931683B2 (ja) 2016-06-08
RU2014147354A (ru) 2015-07-10
JP2013056886A (ja) 2013-03-28
PL2203431T3 (pl) 2012-01-31
ES2592961T3 (es) 2016-12-02
JP2010539187A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
LU92666I2 (fr) Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate
CY1114925T1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
WO2008089105A3 (fr) Analogues de nucléosides antiviraux
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2007079199A3 (fr) Inhibiteurs de métalloprotéases à base de bisamides substitués
DK1984381T3 (da) 6-modificerede bicycliske nukleinsyreanaloger
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MA32498B1 (fr) Compositions pharmaceutiques de rosuvastatine calcium
SE0303480D0 (sv) Benzofuranes
NO20075218L (no) Dermatological compositions and salts for the treatment of dermatological diseases
MY140858A (en) Ampa receptor potentiators
WO2005118558A3 (fr) Composes pyrimidine et leur utilisation
DK1893597T3 (da) AMPA-receptorpotentiatorer
WO2007138462A3 (fr) Formulations orales aqueuses de rispéridone
UA92343C2 (en) Ampa receptor potentiators
JO3721B1 (ar) اعطاء مثبطات ثنائي ببتيديل ببتيداز
RU2005116452A (ru) Модификаторы для эвтектических силуминов